Adachi, Takeya, Kainuma, Keigo, Asano, Koichiro, Amagai, Masayuki, Arai, Hiroyuki, Ishii, Ken J., Ito, Komei, Uchio, Eiichi, Ebisawa, Motohiro, Okano, Mitsuhiro, Kabashima, Kenji, Kondo, Kenji, Konno, Satoshi, Saeki, Hidehisa, Sonobe, Mariko, Nagao, Mizuho, Hizawa, Nobuyuki, Fukushima, Atsuki, Fujieda, Shigeharu, and Matsumoto, Kenji
Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi , introduces the developmental process and details of Strategy 2030. [ABSTRACT FROM AUTHOR]